PURPOSE: In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB). EXPERIMENTAL DESIGN: Patients were randomized (1:1:1) to durvalumab (1,500 mg) plus EP, durvalumab plus tremelimumab (75 mg) plus EP, or EP alone. Treatment effects in PD-L1 and tTMB subgroups were estimated using an unstratified Cox proportional hazards model. RESULTS: The PD-L1 and tTMB biomarker-evaluable populations (BEP) comprised 54.4% (438/805) and 35.2% (283/805) of the intention-to-treat population, respectively. PD-L1 prevalence was low: 5.7%, 25.8%, and 28.3% had PD-L1 expression on ≥1% tumor cells (TC), ≥1% immune cells (IC), and ≥1% TCs or ICs, respectively. OS benefit with durvalumab plus EP versus EP was similar across PD-L1 subgroups, with HRs all falling within the 95% confidence interval (CI) for the PD-L1 BEP (0.47‒0.79). OS benefit with durvalumab plus tremelimumab plus EP versus EP was greater in PD-L1 ≥1% versus <1% subgroups, although CIs overlapped. There was no evidence of an interaction between tTMB and treatment effect on OS (durvalumab plus EP vs. EP, P = 0.916; durvalumab plus tremelimumab plus EP vs. EP, P = 0.672). CONCLUSIONS: OS benefit with first-line durvalumab plus EP in patients with ES-SCLC was observed regardless of PD-L1 or tTMB status. PD-L1 expression may prove to be a useful biomarker for combined treatment with PD-(L)1 and CTLA-4 inhibition, although this requires confirmation with an independent dataset. See related commentary by Rolfo and Russo, p. 652.

Asklepios Lung Clinic Member of the German Center for Lung Research Munich Gauting Germany

AstraZeneca Cambridge United Kingdom

AstraZeneca Gaithersburg Maryland

AstraZeneca Waltham Massachusetts

Cancer and Hematology Centers of Western Michigan Grand Rapids Michigan

Clinic of Medical Oncology UMHAT St Marina Varna Bulgaria

David Geffen School of Medicine at UCLA Los Angeles California

Department of Medical Oncology Hospital Universitario 12 de Octubre Lung Cancer Unit CNIO H120 Complutense University and Ciberonc Madrid Spain

Department of Medicine Section of Hematology Oncology Thoracic Oncology Unit University of Chicago Chicago Illinois

Dnipropetrovsk Medical Academy Dnipro Ukraine

Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Istanbul University Cerrahpaşa Cerrahpaşa School of Medicine Istanbul Turkey

Karl Landsteiner Institute of Lung Research and Pulmonary Oncology Klinik Floridsdorf Vienna Austria

Odessa Regional Oncological Dispensary Odessa Ukraine

Okayama University Hospital Okayama Japan

Omsk Regional Cancer Center Omsk Russian Federation

Petrov Research Institute of Oncology St Petersburg Russian Federation

Samsung Changwon Hospital Sungkyunkwan University School of Medicine Changwon Republic of South Korea

Semmelweis University Budapest Hungary

Thomayer Hospital 1st Faculty of Medicine Charles University Prague Czech Republic

Clin Cancer Res. 2024 Feb 16;30(4):652-654. doi: 10.1158/1078-0432.CCR-23-3087. PubMed

Transl Cancer Res. 2025 Jan 31;14(1):24-28. doi: 10.21037/tcr-24-1711. PubMed

Zobrazit více v PubMed

Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. . First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379:2220–9. PubMed

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:1929–39. PubMed

Goldman JW, Garassino MC, Chen Y, Ozguroglu M, Dvorkin M, Trukhin D, et al. . Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer 2020;149:46–52. PubMed

Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. . Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 2021;39:619–30. PubMed PMC

Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al. . Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 2022;7:100408. PubMed PMC

Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al. . Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 2015;3:1052–62. PubMed

Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity 2018;48:434–52. PubMed PMC

Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. . Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med 2018;24:1441–8. PubMed

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. . Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378:2093–104. PubMed PMC

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, et al. . First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol 2019;37:992–1000. PubMed PMC

Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, et al. . Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol 2020;6:661–74. PubMed PMC

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353–65. PubMed

Gelsomino F, Lamberti G, Parisi C, Casolari L, Melotti B, Sperandi F, et al. . The evolving landscape of immunotherapy in small-cell lung cancer: a focus on predictive biomarkers. Cancer Treat Rev 2019;79:101887. PubMed

Saltos A, Shafique M, Chiappori A. Update on the biology, management, and treatment of small cell lung cancer (SCLC). Front Oncol 2020;10:1074. PubMed PMC

Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. . Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104–10. PubMed PMC

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. . Signatures of mutational processes in human cancer. Nature 2013;500:415–21. PubMed PMC

George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. . Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524:47–53. PubMed PMC

Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. . Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012;482:400–4. PubMed PMC

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189–99. PubMed PMC

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, et al. . Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 2018;33:853–61.e4. PubMed PMC

Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, et al. . Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer 2019;7:87. PubMed PMC

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47. PubMed

Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, et al. . Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol 2016;11:95. PubMed PMC

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9:34. PubMed PMC

Foundation Medicine press release. FoundationOne®CDx Receives FDA Approval as the First Companion Diagnostic to Identify Advanced Cancer Patients with Solid Tumors that are Tumor Mutational Burden-High (TMB-H) and Appropriate for Immunotherapy Treatment with KEYTRUDA® (pembrolizumab). Available from: https://www.foundationmedicine.com/press-releases/2bac198e-d31b-4e95-bfbf-28a55093b8e8.

Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883–95. PubMed

Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, et al. . PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 2019;4:e126908. PubMed PMC

Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csoszi T, et al. . Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol 2020;38:2369–79. PubMed PMC

Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, et al. . Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol 2019;14:237–44. PubMed PMC

Chung HC, Lopez-Martin JA, Kao SC-H, Miller WH, Ros W, Gao B, et al. . Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. J Clin Oncol 36: 15s, 2018(suppl; abstr 8506).

Rudin CM, Kim HR, Navarro A, Gottfried M, Peters S, Csoszi T, et al. . Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC. J Clin Oncol 41: 16s, 2023(suppl; abstr 8503).

Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al. . Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol 2020;15:426–35. PubMed

Herbst RS, Lopes G, Kowalski DM, Nishio M, Wu YL, de Castro Junior G, et al. . Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials. Ann Oncol 2019;30:v916–v7.

Mok TSK, Lopes G, Cho BC, Kowalski DM, Kasahara K, Wu YL, et al. . Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol 2023;34:377–88. PubMed

Paz-Ares L, Langer CJ, Novello S, Halmos B, Cheng Y, Gadgeel SM, et al. . Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407. Ann Oncol 2019;30:v917–v8.

Garassino MC, Gadgeel S, Novello S, Halmos B, Felip E, Speranza G, et al. . Associations of tissue tumor mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic NSCLC. JTO Clin Res Rep 2023;4:100431. PubMed PMC

Stenzinger A, Allen JD, Maas J, Stewart MD, Merino DM, Wempe MM, et al. . Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer 2019;58:578–88. PubMed PMC

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. . Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 2019;19:289–97. PubMed PMC

Owonikoko TK, Dwivedi B, Chen Z, Zhang C, Barwick B, Ernani V, et al. . YAP1 expression in SCLC defines a distinct subtype with T-cell-inflamed phenotype. J Thorac Oncol 2021;16:464–76. PubMed PMC

Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 2021;39:346–60. PubMed PMC

Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. . Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 2018;359:582–7. PubMed PMC

Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, Kuo F, et al. . Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med 2019;25:1715–20. PubMed PMC

Garassino MC, Shrestha Y, Xie M, Lai Z, Spencer S, Dalvi T, et al. . MA16.06 Durvalumab ± tremelimumab + platinum-etoposide in 1L ES-SCLC: exploratory analysis of HLA genotype and survival in CASPIAN. J Thorac Oncol 2021;16:S939.

Xie M, Chugh P, Broadhurst H, Lai Z, Whitston D, Paz-Ares L, et al. . Durvalumab (D) + platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN [abstract]. In:Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022Apr 8–13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT024.

Sivapalan L, Murray JC, Canzoniero JV, Landon B, Jackson J, Scott S, et al. . Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. J Immunother Cancer 2023;11:e005924. PubMed PMC

Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, et al. . Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov 2020;10:1842–53. PubMed PMC

Pizzutilo EG, Pedrani M, Amatu A, Ruggieri L, Lauricella C, Veronese SM, et al. . Liquid biopsy for small cell lung cancer either de novo or transformed: systematic review of different applications and meta-analysis. Cancers 2021;13:2265. PubMed PMC